Clinical Research Informer

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

JUNE 1, 2021

After aducanumab showed promise in 2016, Biogen launched two late-stage trials — then stopped them halfway through, in March 2019, when an analysis concluded the studies would not reach their goal of slowing cognitive and functional impairment in participants. Will they follow the science or will they put a price tag on hope?

Drugs

Drugs Trials Doctors Doctor

Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDA

pharmaphorum

DECEMBER 24, 2021

The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease. The $56,000-a-year price tag for the drug, which has now been cut in half in the US, also hasn’t helped the drugmakers make a case for Aduhelm with US payers.

Drugs

Drugs FDA Approval Trials Marketing

Biogen’s Aducanumab Becomes First Drug Approved for Alzheimer’s in Nearly 20 Years Despite Controversy

XTalks

JUNE 9, 2021

Biogen has been working vigorously over the past couple of years to get its potentially disease-modifying drug Aduhelm (aducanumab) approved for Alzheimer’s disease, and it has finally happened. Aducanumab is a human IgG1 monoclonal antibody that binds to aggregated forms of amyloid beta to help reduce its buildup.

Drugs

Drugs Clinical Trials Clinical Trials Trials

AAIC 2021: Six Ways the Approval of Aducanumab Will Change Alzheimer’s Clinical Trials

XTalks

AUGUST 23, 2021

AAt this year’s Alzheimer’s Association International Conference ( AAIC ), entire sessions were dedicated to discussions of Biogen’s recently-approved, controversial drug Aduhelm (aducanumab), but their focus wasn’t what you’d expect. Now that [aducanumab] is approved, how will this affect clinical trials going forward?”.

Clinical Trials

Clinical Trials Clinical Trials Trials Drugs

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

pharmaphorum

JUNE 8, 2021

That was the damning conclusion of the influential Institute for Clinical and Economic Review (ICER) in the US to yesterday’s approval of Aduhelm (aducanumab), the first new treatment for Alzheimer’s since 2003, which it says has “no evidentiary basis.”

Drugs

Drugs Marketing FDA Approval Trials

FDA Trims Broad Label for Biogen’s Alzheimer’s Drug Amidst Harsh Criticism

XTalks

JULY 12, 2021

The US Food and Drug Administration’s (FDA) recent approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab) was met with a lot of backlash, prompting the health agency to narrow its recommendation of the drug for mild forms of the disease.

Drugs

Drugs Clinical Trials Clinical Trials Trials

Biogen’s Aduhelm rollout goes from bad to worse

pharmaphorum

OCTOBER 21, 2021

As it turned out, Aduhelm (aducanumab) made just $300,000 in the three-month period from July to September, against analysts’ estimates of $12 million, suggesting that few patients are being treated with the $56,000 a year therapy. .

Sales

Sales Doctors Doctor Gene Therapy

Roche’s Early Alzheimer’s Blood Test Gets FDA Breakthrough Device Designation

XTalks

APRIL 18, 2024

The approval of amyloid-beta-targeting therapies like Leqembi and recently discontinued Aduhelm (aducanumab) have come with controversy around their clinical effectiveness. Previously, Roche secured an FDA breakthrough tag for another one of its Alzheimer’s blood tests that detects levels of pTau-181 and ApoE4 (apolipoprotein e4).

Clinical Trials

Clinical Trials Clinical Trials In-Vitro Protein

Biogen updates on its confirmatory Aduhelm trial

pharmaphorum

DECEMBER 17, 2021

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

Trials

Trials Sales Marketing FDA Approval

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go

pharmaphorum

MAY 10, 2022

As with Aduhelm (aducanumab), lecanemab is being filed via the accelerated approval pathway, with the companies seeking a green light on the strength of the results of a phase 2b trial ahead of the readout of the confirmatory Clarity AD trial, due in the autumn.

FDA Approval

FDA Approval Trials Clinical Trials Clinical Trials

Drug Pricing Reform: Never Out of the Headlines

Intouch Solutions

JULY 27, 2021

” they pointed out that the COVID-19 vaccines, and the controversial approval of aducanumab for the treatment of Alzheimer’s disease, represented polar opposites in terms of drug pricing reform. In the case of the vaccines, the U.S. government lowered risk by supporting trials, guaranteeing contracts, and negotiating a lower price.

Drugs

Drugs Marketing Vaccination Vaccine

Viagra ‘should be tested as Alzheimer’s therapy’

pharmaphorum

DECEMBER 7, 2021

That finding could provide some comfort to Biogen and Eisai, whose recently-approved amyloid-targeting drug Aduhelm (aducanumab) is struggling to gain traction in the market on the back of unconvincing efficacy data, safety concerns and a high price tag.

Drugs

Drugs Clinical Trials Clinical Trials Scientist

Clinical Research Informer

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDA

Trending Sources

Biogen’s Aducanumab Becomes First Drug Approved for Alzheimer’s in Nearly 20 Years Despite Controversy

AAIC 2021: Six Ways the Approval of Aducanumab Will Change Alzheimer’s Clinical Trials

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

FDA Trims Broad Label for Biogen’s Alzheimer’s Drug Amidst Harsh Criticism

Biogen’s Aduhelm rollout goes from bad to worse

Roche’s Early Alzheimer’s Blood Test Gets FDA Breakthrough Device Designation

Biogen updates on its confirmatory Aduhelm trial

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go

Drug Pricing Reform: Never Out of the Headlines

Viagra ‘should be tested as Alzheimer’s therapy’

Stay Connected